Logo image of CTSO

CYTOSORBENTS CORP (CTSO) Stock Fundamental Analysis

NASDAQ:CTSO - US23283X2062 - Common Stock

0.9434 USD
+0.01 (+0.84%)
Last: 8/29/2025, 8:14:47 PM
0.9564 USD
+0.01 (+1.38%)
After Hours: 8/29/2025, 8:14:47 PM
Fundamental Rating

2

Taking everything into account, CTSO scores 2 out of 10 in our fundamental rating. CTSO was compared to 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CTSO have multiple concerns. CTSO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CTSO had negative earnings in the past year.
In the past year CTSO has reported a negative cash flow from operations.
In the past 5 years CTSO always reported negative net income.
CTSO had a negative operating cash flow in each of the past 5 years.
CTSO Yearly Net Income VS EBIT VS OCF VS FCFCTSO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -20.32%, CTSO is in line with its industry, outperforming 51.05% of the companies in the same industry.
With a Return On Equity value of -84.15%, CTSO is not doing good in the industry: 60.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -20.32%
ROE -84.15%
ROIC N/A
ROA(3y)-50.29%
ROA(5y)-37.4%
ROE(3y)-134.62%
ROE(5y)-90.6%
ROIC(3y)N/A
ROIC(5y)N/A
CTSO Yearly ROA, ROE, ROICCTSO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

CTSO has a better Gross Margin (73.19%) than 85.26% of its industry peers.
In the last couple of years the Gross Margin of CTSO has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for CTSO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.03%
CTSO Yearly Profit, Operating, Gross MarginsCTSO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

2

2. Health

2.1 Basic Checks

CTSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CTSO has more shares outstanding
CTSO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CTSO is higher compared to a year ago.
CTSO Yearly Shares OutstandingCTSO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CTSO Yearly Total Debt VS Total AssetsCTSO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

CTSO has an Altman-Z score of -7.93. This is a bad value and indicates that CTSO is not financially healthy and even has some risk of bankruptcy.
CTSO's Altman-Z score of -7.93 is on the low side compared to the rest of the industry. CTSO is outperformed by 74.21% of its industry peers.
CTSO has a Debt/Equity ratio of 1.24. This is a high value indicating a heavy dependency on external financing.
CTSO has a worse Debt to Equity ratio (1.24) than 80.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.24
Debt/FCF N/A
Altman-Z -7.93
ROIC/WACCN/A
WACC9.13%
CTSO Yearly LT Debt VS Equity VS FCFCTSO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

CTSO has a Current Ratio of 2.34. This indicates that CTSO is financially healthy and has no problem in meeting its short term obligations.
CTSO has a Current ratio of 2.34. This is comparable to the rest of the industry: CTSO outperforms 45.26% of its industry peers.
CTSO has a Quick Ratio of 1.96. This is a normal value and indicates that CTSO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.96, CTSO is in line with its industry, outperforming 52.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.34
Quick Ratio 1.96
CTSO Yearly Current Assets VS Current LiabilitesCTSO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

5

3. Growth

3.1 Past

CTSO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 68.52%, which is quite impressive.
The Revenue has decreased by -7.81% in the past year.
CTSO shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.36% yearly.
EPS 1Y (TTM)68.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%137.5%
Revenue 1Y (TTM)-7.81%
Revenue growth 3Y-6.23%
Revenue growth 5Y7.36%
Sales Q2Q%-2.81%

3.2 Future

CTSO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.93% yearly.
Based on estimates for the next years, CTSO will show a very strong growth in Revenue. The Revenue will grow by 27.36% on average per year.
EPS Next Y65.11%
EPS Next 2Y32.94%
EPS Next 3Y27.93%
EPS Next 5YN/A
Revenue Next Year0.37%
Revenue Next 2Y10.3%
Revenue Next 3Y16.54%
Revenue Next 5Y27.36%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CTSO Yearly Revenue VS EstimatesCTSO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
CTSO Yearly EPS VS EstimatesCTSO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CTSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTSO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CTSO Price Earnings VS Forward Price EarningsCTSO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTSO Per share dataCTSO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4

4.3 Compensation for Growth

CTSO's earnings are expected to grow with 27.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.94%
EPS Next 3Y27.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CTSO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYTOSORBENTS CORP

NASDAQ:CTSO (8/29/2025, 8:14:47 PM)

After market: 0.9564 +0.01 (+1.38%)

0.9434

+0.01 (+0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05
Inst Owners27.37%
Inst Owner Change-2.11%
Ins Owners8.54%
Ins Owner Change1.46%
Market Cap59.21M
Analysts80
Price Target5.1 (440.6%)
Short Float %2.58%
Short Ratio6.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)115.41%
Min EPS beat(2)71.99%
Max EPS beat(2)158.82%
EPS beat(4)3
Avg EPS beat(4)38.04%
Min EPS beat(4)-116.73%
Max EPS beat(4)158.82%
EPS beat(8)6
Avg EPS beat(8)16.47%
EPS beat(12)7
Avg EPS beat(12)8.26%
EPS beat(16)7
Avg EPS beat(16)-8.03%
Revenue beat(2)1
Avg Revenue beat(2)-1.45%
Min Revenue beat(2)-5.01%
Max Revenue beat(2)2.1%
Revenue beat(4)1
Avg Revenue beat(4)-5.92%
Min Revenue beat(4)-11.18%
Max Revenue beat(4)2.1%
Revenue beat(8)2
Avg Revenue beat(8)-5.09%
Revenue beat(12)4
Avg Revenue beat(12)-4.73%
Revenue beat(16)5
Avg Revenue beat(16)-5.68%
PT rev (1m)0%
PT rev (3m)-28.57%
EPS NQ rev (1m)-7.71%
EPS NQ rev (3m)15.15%
EPS NY rev (1m)17.02%
EPS NY rev (3m)44.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.77%
Revenue NY rev (1m)0.7%
Revenue NY rev (3m)-5.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.73
P/FCF N/A
P/OCF N/A
P/B 5.11
P/tB 7.55
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0.55
BVpS0.18
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.32%
ROE -84.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.19%
FCFM N/A
ROA(3y)-50.29%
ROA(5y)-37.4%
ROE(3y)-134.62%
ROE(5y)-90.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.74%
GM growth 5Y0.03%
F-Score4
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 1.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.58%
Cap/Sales 1.76%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.34
Quick Ratio 1.96
Altman-Z -7.93
F-Score4
WACC9.13%
ROIC/WACCN/A
Cap/Depr(3y)278.83%
Cap/Depr(5y)335.47%
Cap/Sales(3y)7.84%
Cap/Sales(5y)7.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)68.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%137.5%
EPS Next Y65.11%
EPS Next 2Y32.94%
EPS Next 3Y27.93%
EPS Next 5YN/A
Revenue 1Y (TTM)-7.81%
Revenue growth 3Y-6.23%
Revenue growth 5Y7.36%
Sales Q2Q%-2.81%
Revenue Next Year0.37%
Revenue Next 2Y10.3%
Revenue Next 3Y16.54%
Revenue Next 5Y27.36%
EBIT growth 1Y34.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.68%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y55.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y55.77%
OCF growth 3YN/A
OCF growth 5YN/A